Clinical Research Directory
Browse clinical research sites, groups, and studies.
SNAPS Breast Cancer Patient Study Breast Cancer Patients
Sponsor: Immunis.AI
Summary
Differential immunogenomic signatures from peripheral blood CD14 (phagocytic) and CD2 (non-phagocytic) cells have been associated with multiple cancers and disease states. In particular several large clinical studies at Immunis.AI have demonstrated robust immunogenomic signatures in early-stage prostate cancer. Immunis.AI therefore hypothesizes that a peripheral blood immunogenomic signature will identify patients with various stages of breast cancer from healthy negative controls.
Official title: Subtraction Normalized Aggregated Phagocytic Signal in Peripheral Blood of Breast Cancer Patients (SNAPS - Clinical Trial) A NextGen RNASeq Feasibility Study of a Blood-based Model for Early Cancer Detection and Surveillance
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2025-09-01
Completion Date
2027-12-31
Last Updated
2024-03-06
Healthy Volunteers
No
Conditions
Interventions
Blood test
Proprietary immunogenomic signature from peripheral blood CD14 and CD2 cells.
Locations (1)
Duke University
Durham, North Carolina, United States